Editas Medicine (NASDAQ: HSKA) and Heska (NASDAQ:HSKA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, profitability and institutional ownership.
Risk and Volatility
Editas Medicine has a beta of 3.36, meaning that its stock price is 236% more volatile than the S&P 500. Comparatively, Heska has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.
This is a summary of recent ratings and target prices for Editas Medicine and Heska, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Editas Medicine currently has a consensus target price of $48.67, suggesting a potential upside of 50.16%. Heska has a consensus target price of $107.50, suggesting a potential downside of 3.72%. Given Editas Medicine’s higher possible upside, equities research analysts plainly believe Editas Medicine is more favorable than Heska.
Institutional and Insider Ownership
67.2% of Editas Medicine shares are held by institutional investors. Comparatively, 89.2% of Heska shares are held by institutional investors. 5.2% of Editas Medicine shares are held by company insiders. Comparatively, 14.7% of Heska shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Editas Medicine and Heska’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Editas Medicine and Heska’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Editas Medicine||$13.73 million||112.55||-$120.32 million||($2.98)||-10.88|
|Heska||$129.34 million||6.47||$9.95 million||$2.07||53.94|
Heska has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.
Heska beats Editas Medicine on 10 of the 13 factors compared between the two stocks.
About Editas Medicine
Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps. This segment also provides veterinary imaging instruments and services, such as digital radiography solutions and ultrasound systems, as well as sells mobile digital radiography products; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; TRI-HEART Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Its Other Vaccines, Pharmaceuticals and Products segment offers bovine vaccines primarily under the Titanium and MasterGuard brands; biological and pharmaceutical products for other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging. The company sells its products to veterinarians through a field organization and third-party distributors; and trade shows, print advertising, and other distribution relationships. Heska Corporation has product development partnership and licensing agreement with MBio Diagnostics, Inc. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.